RIYADH, Saudi Arabia, Oct 25 (Bernama-GLOBE NEWSWIRE) — The King Faisal Specialist Hospital and Research Centre (KFSH&RC) is proud to announce the launch of the inaugural phase of its clinical pharmacogenomics service within its Heart Center. This pioneering service leverages the patient’s DNA to tailor drug dosages and selections, heralding a new era in healthcare that prioritizes personalized treatment for each individual. This groundbreaking approach is poised to enhance treatment outcomes and reduce potential harm.
KFSH&RC’s experts have said that this analysis empowers physicians to prescribe medications customized to each patient, factoring in their unique health conditions and genetic traits. Patients’ responses to pharmaceuticals can significantly differ based on their genetic profiles. As a result, what proves effective for one patient may have minimal impact in another. It is worth noting that statistics reveal that 15% of hospital admissions stem from adverse drug reactions, imposing substantial financial and human burdens on healthcare systems across the globe.
